{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:29:41Z","timestamp":1787725781287,"version":"build-2784847793"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secondary immunodeficiency (SID) arises from malignancy, immunomodulatory therapies, organ dysfunction, chronic infection, malnutrition, and aging. Despite its increasing prevalence, SID remains conceptualized within disease-specific silos, resulting in inconsistent diagnostic standards and fragmented management across specialties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using the PRISMA 2020 guidelines and a prospectively registered OSF protocol (6qvkx), a systematic, qualitative synthesis was conducted, comprising structured screening, standardized data extraction, and a design-specific risk-of-bias assessment. A search of the MEDLINE, Embase, Scopus, and Web of Science databases resulted in 11,968 records. A Python-assisted fuzzy-matching algorithm identified 9,295 duplicate records (78%), which were confirmed in Zotero. Following deduplication, 2673 unique studies were screened; 100 met the predefined PICOS criteria and were included in the qualitative synthesis. No primary data were collected. The primary reviewer selected the studies and extracted data manually, using Python only for descriptive summarization. Thematic synthesis was presented along three predetermined axes of analysis:\n                      <jats:italic>humoral dysfunction, cellular disruption, and innate immune dysregulation.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Humoral failure, cellular disruption, and innate immune dysregulation were identified as 3 immunologic pathways common across all included clinical domains. A significant difference was noted in the type of diagnostic criteria used: IgG thresholds were used in 78% of the hematological malignancy studies and 42% of the HIV\/malnutrition studies, whereas the functional assessment of antibody in the former was employed in 32% of studies compared to 67% of the latter, presumably due to the superior clinical correlation in chronic infection and nutritional deficiency settings. The most common outcome reported was infection burden (range 63-85%). Structured qualitative convergence mapping was used to create an exploratory conceptual risk stratification framework based on variables that met preset cross-domain reproducibility criteria. The framework is designed to provide a structured clinical reasoning tool, organized around convergent cross-domain evidence, which requires prospective validation before use in the clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Three immunological pathways converge in the selected SID-inducing conditions: humoral dysfunction, cellular disruption, and innate immune dysfunction. The proposed framework provides a structured approach to risk evaluation and management across specialties and resource settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/osf.io\/6qvkx<\/jats:ext-link>\n                      , identifier 6qvkx.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1866662","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:57:30Z","timestamp":1787723850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking secondary immunodeficiency: a cross-domain pathway framework for risk stratification"],"prefix":"10.3389","volume":"17","author":[{"given":"Iqra","family":"Mumtaz","sequence":"first","affiliation":[{"name":"Management of Digital Transformation (MDT), IMT School for Advanced Studies Lucca","place":["Lucca, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12931-024-02991-z","article-title":"The clinical application of metagenomic next-generation sequencing in immunocompromised patients with severe respiratory infections in the ICU","volume":"25","author":"Zhao","year":"2024","journal-title":"Respir Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1142\/s2661341724300027","article-title":"The importance of monitoring baseline and regular immunoglobulin levels in managing secondary hypogammaglobulinemia in rheumatic diseases: a case report and systematic review","volume":"24","author":"Yeung","year":"2024","journal-title":"J Clin Rheumatol Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.03.010","article-title":"Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review","volume":"18","author":"Wijetilleka","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa255","article-title":"Possible diagnostic delays and missed prevention opportunities in pneumocystis pneumonia patients without HIV: analysis of commercial insurance claims data, United States, 2011\u20132015","volume":"7","author":"Weycker","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances","article-title":"Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients","volume":"5","author":"Vijenthira","year":"2021","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq798","article-title":"Epidemiology, clinical features, and outcomes of pneumonia in patients with chronic kidney disease","author":"Viasus","year":"2011","journal-title":"Nephrol Dialysis Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.09.003","article-title":"Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation","volume":"32","author":"Ueda","year":"2017","journal-title":"Blood Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70310","article-title":"Evidence\u2010 and consensus\u2010based recommendations for the screening, diagnosis, and management of secondary hypogammaglobulinemia in patients with systemic autoimmune rheumatic diseases by the Taiwan College of Rheumatology Experts","author":"Tsao","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35036","article-title":"A unified component-based data-driven framework to support interoperability in the healthcare systems","volume":"10","author":"Torab-Miandoab","year":"2024","journal-title":"Heliyon"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-020-0173-8","article-title":"Contributions of age-related thymic involution to immunosenescence and inflammaging","author":"Thomas","year":"2020","journal-title":"Immun Aging"},{"key":"B11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/pathogens13030259","article-title":"Infections in disorders of immune regulation","volume":"13","author":"Thangaraj","year":"2024","journal-title":"Pathogens"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ackd.2019.01.004","article-title":"Immune dysfunction and risk of infection in chronic kidney disease","volume":"26","author":"Syed-Ahmed","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.021","article-title":"Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality","author":"Sutherland","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency \u2013 causes and approach to diagnosis","volume":"16","author":"Srivastava","year":"2016","journal-title":"Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101354","article-title":"Network approaches for dissecting the immune system","volume":"23","author":"Shi","year":"2020","journal-title":"iScience"},{"key":"B18","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/jcm14041203","article-title":"Real-world effectiveness, safety, and tolerability of facilitated subcutaneous immunoglobulin 10% in secondary immunodeficiency disease: A systematic literature review","volume":"14","author":"Dimou","year":"2025","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"108931","DOI":"10.1016\/j.clim.2022.108931","article-title":"Health-related quality of life in primary immunodeficiencies: Impact of delayed diagnosis and treatment burden","volume":"236","author":"Anderson","year":"2022","journal-title":"Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.01.002","article-title":"Proceedings from the inaugural Artificial Intelligence in Primary Immune Deficiencies (AIPID) conference","volume":"153","author":"Rivi\u00e8re","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate health inequities","volume":"67","author":"O\u2019Neill","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to hypogammaglobulinemia and infections post-rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common variable immunodeficiency disorders: Division into distinct clinical phenotypes","volume":"112","author":"Chapel","year":"2008","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.751374","article-title":"Physical activity and nutritional influence on immune function: an important strategy to improve immunity and health status","volume":"12","author":"Shao","year":"2021","journal-title":"Front Physiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.3390\/ijms21103422","article-title":"Molecular mechanisms of premature aging in hemodialysis: The complex interplay between innate and adaptive immune dysfunction","volume":"21","author":"Losappio","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1672413","article-title":"Secondary antibody deficiencies: What\u2019s around the corner","volume":"16","author":"Lagnese","year":"2025","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13336","article-title":"Risk stratification of immunocompromised children, including pediatric transplant recipients at risk of severe respiratory syncytial virus disease","volume":"23","author":"Science","year":"2019","journal-title":"Pediatr Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06329-2","article-title":"Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis","volume":"41","author":"Sch\u00e4fer","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Santos","year":"2024","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07238-x","article-title":"Depleting myeloid-biased hematopoietic stem cells rejuvenates aged immunity","author":"Ross","year":"2024","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.067561","article-title":"SARS-CoV-2 vaccine-induced seroconversion and immune correlates in patients with hematological Malignancies. A real world study","author":"Nass","year":"2025","journal-title":"Oncol Res Featuring Preclinical Clin Cancer Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707914","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12016-025-09103-9","article-title":"Immunodeficiencies in adults: key considerations for diagnosis and management","volume":"68","author":"Regina","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.4.2.219","article-title":"Reimmunization after hematopoietic stem cell transplantation","volume":"4","author":"MaChado","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"B38","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12885-021-08451-x","article-title":"Infection risks in multiple myeloma: A systematic review and meta-analysis of randomized trials from 2015 to 2019","volume":"21","author":"Balmaceda","year":"2021","journal-title":"BMC Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2015-309060","article-title":"How to use immunoglobulin levels in investigating immune deficiencies","volume":"101","author":"Ladomenou","year":"2016","journal-title":"Arch Dis Childhood Educ Pract"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.3390\/cells12232714","article-title":"Innate immunity and CKD: Is there a significant association","volume-title":"Cells","author":"Plonsky-Toder","year":"2023"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/febs.17116","article-title":"Genetic and epigenetic dysregulation of innate immune mechanisms in autoinflammatory diseases","volume":"291","author":"Pich","year":"2024","journal-title":"FEBS J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7196\/samj.8965","article-title":"Recommendations for the use of immunoglobulin therapy for immunomodulation and antibody replacement","volume":"104","author":"Peter","year":"2014","journal-title":"South Afr Med J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.01.029","article-title":"Metagenomic next-generation sequencing for the diagnosis of suspected pneumonia in immunocompromised patients","volume":"82","author":"Peng","year":"2021","journal-title":"J Infect"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1722579","article-title":"To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies","author":"Paulsen","year":"2026","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12079","article-title":"HIV\u2010associated chronic immune activation","author":"Paiardini","year":"2013","journal-title":"Immunol Rev"},{"key":"B48","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/v17121615","article-title":"CAR-T cell therapy for HIV cure: current challenges, advances, and future directions","volume":"17","author":"Padurariu-Covit","year":"2025","journal-title":"Viruses"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-46923-x","article-title":"Elevated plasma IgG is associated with improved treatment response and survival in advanced non-small cell lung cancer patients treated with anti-PD1 therapy","author":"Ohkuma","year":"2026","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015477","article-title":"Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma","volume":"9","author":"O\u2019Donnell","year":"2025","journal-title":"Blood Adv"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.01.011","article-title":"American Society for Transplantation and Cellular Therapy Series, #6: Management of invasive candidiasis in hematopoietic cell transplantation recipients","volume":"29","author":"Neofytos","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological Malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur J Hematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","author":"Mears","year":"2023","journal-title":"J Neuroimmunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16331","article-title":"Hypogammaglobulinemia during rituximab treatment in multiple sclerosis: A Swedish cohort study","author":"Hallberg","year":"2024","journal-title":"Eur J Neurol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010159","article-title":"The many faces of immune activation in HIV-1 infection: a multifactorial interconnection","volume":"11","author":"Mazzuti","year":"2023","journal-title":"Biomedicines"},{"key":"B59","doi-asserted-by":"publisher","first-page":"100424","DOI":"10.1016\/j.edurev.2021.100424","article-title":"Moving qualitative synthesis research forward in education: a methodological systematic review","volume":"35","author":"Maeda","year":"2021","journal-title":"Educ Res Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.11.001","article-title":"Immune dysregulation","author":"Long","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2017.07.023","article-title":"Framework for using risk stratification to improve clinical preventive service guidelines","volume":"54","author":"Lin","year":"2017","journal-title":"Am J Prev Med"},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1111\/apha.70057","article-title":"Neutrophil function in patients with chronic kidney disease: A systematic review and meta\u2010analysis","volume-title":"Acta Physiologica","author":"Lauxen","year":"2025"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1626082","article-title":"Autoimmune disease: Genetic susceptibility, environmental triggers, and immune dysregulation. Where can we develop therapies","volume-title":"Front Immunol.","author":"Kumar","year":"2025"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01498-0","article-title":"Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018","volume":"27","author":"Kinyoki","year":"2021","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1635094","article-title":"Secondary antibody deficiencies in the modern era: Emerging trends, diagnostic pitfalls, and advances in personalized management","volume-title":"Front Immunol.","author":"Elkhalifa","year":"2025"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.74","article-title":"Vaccination in patients with primary immune deficiency, secondary immune deficiency, and autoimmunity with immune regulatory abnormalities","volume":"7","author":"Eibl","year":"2015","journal-title":"Immunotherapy"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01120-5","article-title":"Determinants and reference ranges of serum immunoglobulins in middle-aged and elderly individuals: A population-based study","volume":"41","author":"Khan","year":"2021","journal-title":"J Clin Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12016-025-09116-4","article-title":"Bridging the gap in secondary antibody deficiencies: Current evidence and unmet needs in diagnosis and management with immunoglobulin replacement","volume":"68","author":"Kan","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1098326","article-title":"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma: A systematic literature review","volume":"13","author":"Jolles","year":"2023","journal-title":"Front Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"101020","DOI":"10.1016\/j.blre.2022.101020","article-title":"Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel","author":"Jolles","year":"2022","journal-title":"Blood Rev"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00293","article-title":"Causes and consequences of innate immune dysfunction in cirrhosis","author":"Irvine","year":"2019","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803041","article-title":"Neutrophils sequestered in the liver suppress the proinflammatory response of Kupffer cells to systemic bacterial infection","author":"Holub","year":"2009","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2024.45.240057","article-title":"Primary immunodeficiency: Specific antibody deficiency with normal IgG","volume":"45","author":"Hatcher","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/pai.14161","article-title":"Rituximab\u2010to\u2010vaccine interval on SARS\u2010CoV\u20102 immunogenicity in children: The potential role of prior natural infection","author":"Gualtieri","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"B75","doi-asserted-by":"crossref","DOI":"10.1093\/cei\/uxac070","article-title":"British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy","volume-title":"Clin Exp Immunol.","author":"Grigoriadou","year":"2022"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121314","article-title":"Immunosenescence: Aging and immune system decline","volume":"12","author":"Goyani","year":"2024","journal-title":"Vaccines"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy209.019","article-title":"149. Immunogenicity, safety, and post-hoc efficacy assessment of the adjuvanted recombinant zoster vaccine in adults with hematologic Malignancies: A phase 3, randomized clinical trial","author":"Dagnew","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0000000000000412","article-title":"Bruton tyrosine kinase inhibitors","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1001\/jamaoncol.2024.4351","article-title":"Implementing resource-stratified guidelines in LMICs: More issues than solutions","volume":"10","author":"Baral","year":"2024","journal-title":"JAMA Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.03.025","article-title":"Long-term clinical outcome of antibody replacement therapy in humoral immunodeficient adults with respiratory tract infections","author":"van Kessel","year":"2017","journal-title":"EBioMedicine"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/tid.70076","article-title":"Current practice patterns and educational needs of the ESCMID Study Group for infections in compromised hots","volume":"27","author":"Giannella","year":"2025","journal-title":"Transplant Infect Dis"},{"key":"B82","article-title":"Immunoglobulin replacement to prevent infections in people with hematological Malignancies and hematopoietic stem cell transplantation","volume-title":"Cochrane Database Syst Rev.","author":"Chai","year":"2024"},{"key":"B83","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological Malignancies: A systematic review and meta-analysis","volume":"7","author":"Chai","year":"2022","journal-title":"Blood Adv"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-026-00813-z","article-title":"Pretreatment immunoglobulin profiles and survival outcomes in hematologic Malignancies and autoimmune cytopenias: A comparative cohort analysis","author":"Gerek","year":"2026","journal-title":"BMC Immunol"},{"key":"B85","article-title":"Risk prediction in people living with human immunodeficiency virus: Are we hitting the target","volume-title":"Clin Infect Dis.","author":"Galaviz","year":"2019"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2020.1807328","article-title":"A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological Malignancies and stem cell transplants","volume":"16","author":"Bonet","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative Malignancies","volume":"34","author":"Friman","year":"2016","journal-title":"Hematol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1055\/a-2500-2121","article-title":"Vaccination against respiratory infections in the immunosenescent older adult population: Challenges and opportunities","volume":"46","author":"Ecarnot","year":"2024","journal-title":"Semin Respir Crit Care Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1586\/1744666x.2014.902314","article-title":"Secondary antibody deficiency","volume":"10","author":"Duraisingham","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Autoimmun Highlights"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2329378","article-title":"Severe and persistent immunoparesis during induction or maintenance therapy in non-transplant patients with multiple myeloma is a poor prognostic sign","volume":"29","author":"Chen","year":"2024","journal-title":"Hematology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"9736","DOI":"10.3390\/ijms25179736","article-title":"Safety and efficacy of bispecific antibodies in adults with large B-cell lymphomas: A systematic review of clinical trial data","volume":"25","author":"Bayly-McCredie","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clml.2019.10.004","article-title":"Risk of infection associated with ibrutinib in patients with B-cell Malignancies: A systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Ball","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary immunodeficiency in hematological Malignancies: Focus on multiple myeloma and chronic lymphocytic leukemia","volume":"12","author":"Allegra","year":"2021","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091549","article-title":"Immunoglobulin G trough levels and infection risk in adults with inborn errors of immunity receiving immunoglobulin therapy","volume":"61","author":"Akta\u015f","year":"2025","journal-title":"Medicina"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae145","article-title":"Adopting prospective antimicrobial stewardship (AMS) practice in high-risk immunosuppressed groups: An urgent call to action in the era of antimicrobial resistance (AMR","volume":"6","author":"Agrawal","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2016.1208085","article-title":"Prophylactic immunoglobulin therapy in secondary immune deficiency \u2013 An expert opinion","volume":"12","author":"Agostini","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.07.039","article-title":"The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis","volume":"36","author":"Aalst","year":"2018","journal-title":"Vaccine"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928062","article-title":"Secondary immune deficiency and primary immune deficiency crossovers: hematological malignancies and autoimmune diseases","volume":"13","author":"Ballow","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1866662\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:57:34Z","timestamp":1787723854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1866662\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":100,"alternative-id":["10.3389\/fimmu.2026.1866662"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1866662","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1866662"}}